<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079584</url>
  </required_header>
  <id_info>
    <org_study_id>fwa00003543</org_study_id>
    <nct_id>NCT02079584</nct_id>
  </id_info>
  <brief_title>Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant</brief_title>
  <official_title>Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this registry are to measure the outcomes, cost, adherence pattern and
      experience of patients treated as outpatients with rivaroxaban after being diagnosed with
      blood clots in the emergency department. The investigators hypothesize that patients will
      have a relatively low rate of adverse events and higher adherence than has been reported
      historically for warfarin treatment. Patients will be scheduled for follow up care with one
      of Dr. Kline's Outpatient Thrombosis clinics at Methodist Hospital, Eskenazi Health Services
      and the Baylor University Medical Center (Dallas, TX) after diagnosis and treatment of
      pulmonary embolism (PE) or deep vein thrombosis (DVT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Information will be obtained from the patient medical records, past medical history, physical
      examination at initial outpatient clinic visit 30 days (+/- 14 days) and 6 months or 180 days
      (+/- 14 days) post diagnosis or start of treatment, then annual follow ups for up to 5 years.
      The data will be collected and stored in a database, the IU RedCap database system will be
      used to develop a database and store information .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Clot Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>The primary outcome is clot recurrence, with the rivaroxaban cohort expected to be equivalent or improved with warfarin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>Bleeding that requires change in therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>5 years</time_frame>
    <description>Number of patients discontinuing anticoagulation in first 30 days and reason why</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <description>A study group taken from existing anticoagulant clinics treated with warfarin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>A group seen in the rivaroxaban clinic under study.</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      A blood sample will be obtained at the initial outpatient visit within 30 days (+/- 14 days)
      post diagnosis and/or start of treatment and at the 180 day (+/- 14 days) follow up post
      treatment visit and at each annual visit for up to 5 years.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Heterogeneous group of patients pulled primarily from an emergency department population,
        diagnosed with low-risk VTE.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion:

          -  DVT or PE diagnosed on imaging:

          -  Systolic always&gt;100 mm Hg in absence of history of low blood pressure

          -  No contraindication to anticoagulation treatment (active bleeding or high risk
             postoperative status, creatinine clearance &lt; 30 ml/min, history of heparin induced
             thrombocytopenia or warfarin skin necrosis);

          -  No other medical condition requiring hospital treatment (sepsis, new or decompensated
             existing organ failure, intractable pain);

          -  No social condition requiring hospital treatment (homelessness with history of
             non-adherence to treatment, suspected neglect or abuse, incarceration, untreated
             psychosis, severe alcohol or drug dependency);

          -  No coagulopathy or current anticoagulant resulting in an INR&gt;1.7, or thrombocytopenia
             (platelet count &lt; 50,000/uL);

          -  No need for supplemental oxygen (no respiratory distress and pulse ox always &gt;94%)

        Exclusion:

        - If active cancer, POMPE-C &lt;6%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey A Kline, MD</last_name>
    <phone>3176700541</phone>
    <email>jefkline@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darren M Beam, MD</last_name>
    <phone>3178803900</phone>
    <email>dmbeam@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey A Kline, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey A Kline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beam DM, Kahler ZP, Kline JA. Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis. Acad Emerg Med. 2015 Jul;22(7):788-95. doi: 10.1111/acem.12711. Epub 2015 Jun 25.</citation>
    <PMID>26113241</PMID>
  </reference>
  <reference>
    <citation>Kahler ZP, Beam DM, Kline JA. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban. Acad Emerg Med. 2015 Jul;22(7):796-802. doi: 10.1111/acem.12713. Epub 2015 Jun 25.</citation>
    <PMID>26111453</PMID>
  </reference>
  <results_reference>
    <citation>Kline JA, Kahler ZP, Beam DM. Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance. Patient Prefer Adherence. 2016 Apr 15;10:561-9. doi: 10.2147/PPA.S104446. eCollection 2016.</citation>
    <PMID>27143861</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Vice Chair of Research</investigator_title>
  </responsible_party>
  <keyword>Patient Compliance</keyword>
  <keyword>Target Specific Anticoagulant</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

